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Expression profiling of bronchopulmonary dysplasia <p>The expression profiles of umbilical cords from premature newborns reveal distinct patterns, including changes in the expression of  chromatin remodeling factors, associated with the development of bronchopulmonary dysplasia.</p>
Abstract
Background: One-third to one-half of all infants born before the 28th week of gestation develop
bronchopulmonary dysplasia (BPD). Inflammatory regulators appear to be involved in the
pathogenesis of BPD, possibly beginning in fetal life. To evaluate the feasibility of using expression
profiling in umbilical cord tissue to discover molecular signatures for developmental staging and for
determining risk of BPD, we conducted a cross-sectional study of infants born at less than 28 weeks
of gestation (n = 54). Sections of umbilical cord were obtained at birth from 20 infants who later
developed BPD and from 34 of their peers who did not develop BPD.
Results:  Umbilical cord expression profiles at birth exhibited systematic differences in
bioenergetic pathways with respect to gestational age. Infants who subsequently developed BPD
had distinct signatures involving chromatin remodeling and histone acetylation pathways, which
have previously been implicated in several adult onset lung diseases. These findings are consistent
with prior work on inflammatory processes and bioenergetics in prematurity.
Conclusion:  T h i s  s t u d y  o f  g e n e  e x p r e s s i o n  o f  t h e  newborn umbilical cord implicates the
chromatin remodeling pathways in those premature infants who subsequently develop BPD. Larger
sample sizes will be required to generate prognostic markers from umbilical cord profiles.
Background
The lung disorder bronchopulmonary dysplasia (BPD) occurs
in 20% to 40% of infants born at under 1,000 g and before 28
completed weeks of gestation [1-4] and it is the second lead-
ing cause of death among infants born within this gestational
age [5]. Previously identified prenatal factors that are associ-
ated with the development of BPD include surfactant defi-
ciency and maternal infection, including chorioamnionitis
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[6]. Among the multiple postnatal environmental factors and
neonatal conditions that have been linked to the development
of BPD are supplemental oxygen exposure, barotrauma from
ventilation, the presence of patent ductus arteriosus, and neo-
natal infection.
Little attention has been directed to the genetics of BPD risk
or the physiologic pathways, measurable at the time of deliv-
ery, that predispose preterm infants to BPD. Inflammatory
mediators, including cytokines and growth factors, appear to
be involved in the development of BPD [7], and their activity
can be upregulated by inflammatory processes that might
begin prenatally and affect the fetus via the placenta [6,8].
For example, chorioamnionitis and funisitis are accompanied
by alterations in the expression of inflammatory mediators
[9].
The placenta and umbilical cord tissue appear both to reflect
and influence the intrauterine environment. What remains
unclear is the extent to which biologic markers obtained from
the umbilical cord might have clinical and developmental cor-
relates in the fetus in both the prenatal and perinatal periods.
Given the multiple tissue types in the umbilical cord that are
also present in the placenta [10-12], we hypothesize that the
umbilical cord genomic signatures may relate to the overall
physiologic state of the maternal-infant unit. In this study we
have explored this hypothesis by examining the relationships
between human gene expression in the umbilical cord at the
time of birth and subsequent BPD, defined as the require-
ment for supplemental oxygen at 36 weeks postmenstrual
age. This also allowed us to identify characteristics of the pre-
term infant at risk for developing BPD.
Results
Of the 72 umbilical cord samples collected for this study, 54
contained at least the minimum of 7 µg RNA required for
hybridization (13 did not) and were from infants who sur-
vived to 36 weeks postmenstrual age (5 died), and therefore
at risk for BPD. All expression data are available in the
National Center for Biotechnology Information's Gene
Expression Omnibus repository (GSE8586).
The infants included in this study were slightly more mature
than those in the Extremely Low Gestational Age Newborn
(ELGAN) study [13] as a whole (Table 1). This may explain
why they had a higher survival rate and lower incidences of
BPD and retinopathy of prematurity.
Infants with and without BPD exhibited minimal differences
in maternal characteristics, including cause of delivery, ante-
natal steroid exposure, race, or histopathologic evidence of
chorioamnionitis (Table 2). Infants who developed BPD were
of lower birth weight and less mature gestational age,
required more days of supplemental oxygen and ventilation,
and had higher rates of retinopathy of prematurity. They did
not differ in sex ratio or rates of patent ductus arteriosus, and
had a modestly higher rate of sepsis (Table 3).
Unsupervised learning revealed inhomogeneous clustering of
the sample by gestational age (27 to 28 weeks versus < 27
weeks; data not shown) and by presence of BPD (BPD versus
control; Figure 1). Similarly, principal components analysis of
the 54 samples across the 54,675 measured transcripts
revealed partial overlap of the samples across the two groups
(Figure 2). Single gene differential gene expression analysis
revealed no genes with a q value (a measure of false discovery
rate [FDR] [14]) below 0.05 or an uncorrected P value below
10-6. The high FDR confirmed that the overlap between the
two classes of infants was high; therefore, we explored sys-
tematic differences in pathways rather than individual genes,
as others have done with similarly subtle differences across
human samples [15].
The gene pathways most differentially expressed by gesta-
tional age category were those related to oxidative phosphor-
ylation, mitochondrial energy metabolism, and DNA repair
(Table 4). None of the genes within these pathways by them-
selves were significantly differentially expressed, but the q
value for the entire set of genes within each pathway (of the
Table 1
Clinical outcomes of the ELGAN (n = 1508) study population as compared with the study sample (n = 54)
Outcome ELGAN Current cohort P
Mortality 21% 11% 0.553
BPD 50% 37% 0.095
NEC (definite disease) 7% 7% 0.459
ROP 62% 48% 0.041
IVH 25% 23% 0.749
GA < 27 weeks 71% 52% < 0.01
BPD, bronchopulmonary dysplasia; ELGAN, Extremely Low Gestational Age Newborn; NEC, Necrotizing Entercolitis (a serious infection of the 
bowel); IVH, Intraventricular Hemorrhage (bleeding in the brain); ROP, Retinopathy of Prematurity (a disease that affects immature vasculature in 
the eyes of premature babies causing significantly decreased vision); GA, Gestational Age.http://genomebiology.com/2007/8/10/R210 Genome Biology 2007,     Volume 8, Issue 10, Article R210       Cohen et al. R210.3
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more than 600 sets evaluated) was below 0.0001, as calcu-
lated using the sigPathway package [16].
When the samples were evaluated comparing infants with
BPD versus those without BPD, the most differentially
expressed gene pathways included the aforementioned
bioenergetic pathways, as well as histone acetyltransferase
binding activity and chromatin remodeling pathways (Table
5). Although the individual genes within these pathways were
not significantly differentially expressed, the expression of
the entire 'chromatin packaging' pathway relative to the over-
all transcriptome was highly significantly differentially
expressed (Figure 3). The ten most differentially expressed
genes of those in chromatin remodeling pathways are shown
in Figure 4 to illustrate how this finding is only a trend at the
individual gene level.
Discussion
Microarray profiling has been used to classify and predict
human disease, but this technique has not yet been applied
widely to the investigation of diseases of the premature new-
born infant. Expression analysis has proved informative in
murine models of fetal and postnatal lung injury [17]. Neona-
tal lung samples, however, are not routinely available. Umbil-
ical cords are routinely available, and their availability has
allowed us to explore expression profiles at birth with respect
to gestational age and subsequent development of BPD. This
has provided a rare opportunity to examine the influence of
fetal physiology on postnatal health and development using
the multiple tissues in umbilical cords as a proxy for a wide
variety of tissues in the maternal-fetal unit.
Gene expression signatures alone provide imperfect cluster-
ing of different gestational age groups in the unsupervised
analyses. For this reason, as expected, the single gene differ-
ential expression measures were fraught with high false dis-
covery rates. However, the supervised analysis at the level of
entire pathways [15] revealed highly significant distinctions
for both gestational age and for the subsequent development
of BPD.
Several biologic pathways have emerged from this investiga-
Table 2
Baseline characteristics of mothers and placentas related to infant outcomes in terms of BPD
Characteristic No BPD (n [%]) BPD (n [%]) P
Preterm labor 20 (58.8) 8 (40) 0.146
Pregnancy-induced hypertension 2 (5.9) 4 (20) 0.127
Cesarean section 26 (76.5) 16 (80) 0.522
Antenatal glucocorticoids 21 (61.8) 14 (70) 0.379
Nonwhite race 11 (32.4) 9 (45) 0.26
Chorioamnionitis
Neutrophils in plate 9 (26.5) 7 (38.9) 0.27
Neutrophils in cord 13 (40.6) 5 (33.3) 0.441
BPD, bronchopulmonary dysplasia.
Table 3
Characteristics of infants in relation to the primary outcome BPD
Characteristic No BPD BPD P
Birth weight (g; median [range]) 975 (532 to 1,360) 695 (460 to 1,080) < 0.005
Gestational age < 27 weeks (n [%]) 13 (38.2) 15 (75) 0.009
Male (n [%]) 19 (55.9) 12 (60) 0.497
Sepsis (suspected or confirmed; n [%]) 2 (5.9) 3 (15.8) 0.239
PDA (suspected or definite; n [%]) 24 (72.7) 14 (73.7) 0.603
ROP (n [%]) 13 (38.2) 13 (68.4) 0.03
Supplemental oxygen (days; median [range]) 31.5 (2 to 88) 68 (37 to 91) < 0.005
Mechanical ventilation (days; median [range]) 3 (0 to 38) 37 (1 to 77) < 0.005
BPD, bronchopulmonary dysplasia; ROP(Retinopathy of Prematurity, a disease that affects immature vasculature in the eyes of premature babies 
leading to significantly decreased vision). PDA (Patent Ductus Arteriosus, a persistent connection between the aorta and the pulmonary artery).Genome Biology 2007, 8:R210
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tion, characterizing different early physiologic states:
bioenergetics (Krebs cycle, mitochondrial function, and oxi-
dative phosphorylation), transporter activity, DNA synthesis
and repair, and chromatin remodeling. However, the latter
pathway was consistently present at a frequency greater than
expected by chance alone (it was enriched) in the compari-
sons of all infants with BPD compared with control infants.
These findings are consistent with the earlier referenced sin-
gle gene investigations of prematurity implicating inflamma-
tory and bioenergetic processes [6-9,18].
Chromatin remodeling
The chromatin remodeling apparatus is involved in the
inflammatory pathways in adult lung disease [19]. Indeed,
glucocorticoids (one of the mainstays of therapy for pulmo-
nary diseases) reverses histone acetylation of activated
inflammatory genes by binding liganded glucocorticoid
receptors to coactivators, by recruiting histone deacetylase-2
to the activated transcription complex [19-21]. However, to
our knowledge, this is the first documentation in human pre-
term neonates of the relative activity of the histone acetyla-
tion/chromatin remodeling pathway at birth in individuals
who subsequently develop BPD. This intersection with the
pathophysiology of chronic obstructive pulmonary disease,
although very limited, does raise the question of whether a
s u b s e t  o f  i n f a n t s  w i t h  B P D  a n d  a d u l t s  w i t h  c h r o n i c
obstructive pulmonary disease share a common vulnerability
that is exposed by different stressors. Such commonality
might have practical import for prevention and treatment
[21].
In our study, the proportions of infants exposed to antenatal
glucocorticoids were similar in infants who did and those who
did not develop BPD. Thus, differential administration of cor-
ticosteroids did not distort the relationship between gene
expression and development of BPD.
Bioenergetic pathways
Differentially expressed energy pathways seen in younger
premature infants when compared with older premature
infants suggest that the timing of delivery may have a global
effect on energy metabolism. Although human data are lack-
ing, preterm rats tend to have diminished mitochondrial
content and function compared with term born rats [22]. The
sets of genes characteristic of oxidative phosphorylation and
other bioenergetics were expressed at lower levels in BPD
infants than in control infants and are also developmentally
regulated, with lower levels of expression in the least mature.
Consequently, in this small sample we could not separate a
gestational age effect from a BPD propensity.
In summary, this study of RNA expression profiles in umbili-
cal cord tissue demonstrates the potential of this technology
in investigations of perinatal and postnatal disorders.
Because chromatin remodeling pathways appeared to be dif-
ferentially regulated in umbilical cord tissues of the subse-
quently BPD-affected neonates, therapeutic modalities that
are being explored for treatment of adult pulmonary diseases
with similar molecular pathophysiology (for example, ster-
oids with fewer side effects such as RU24858 and RU40066
[21] and antioxidants [23,24]) may hold considerable new
promise for those infants who are at risk for BPD. The ana-
lytic methodologies used here might also be sufficiently
robust to identify individuals who are at risk. Although entire
pathways were significantly differentially regulated between
BPD and control infants, multigenic predictors based on
these pathways did not exhibit strong performance, and
identification of more predictive biomarkers will require
larger premature neonate sample sizes
Materials and methods
The study population consisted of a subset of preterm infants
born at one of three centers (Brigham and Women's Hospital,
Beth Israel Deaconess Medical Center, and Wake-Forest
Table 4
Differentially expressed gene sets for gestational age under 27 weeks versus 27 to 28 weeks
Gene set/pathway NTk q value NEk q value
Coenzyme metabolism (GO:0006731) 0.0 0.0
Mitochondrial inner membrane (GO:0005740) 0.0 0.0
Ribonucleotide biosynthesis processing (GO:0009260) 0.0 0.0
Mitochondrial matrix (GO:0005759) 0.0 0.08
Citrate cycle TCA cycle (GO:0006099)/Oxidative phosphorylation (KEGG) 0.0 0.1
Shown here are the pathways (with redundant pathways removed) that were ranked at the top of the list of those differentially expressed by two 
measures of false discovery: the NTk q value and the NEk q value. The NTk q value corresponds to the degree to which genes within a set/pathway 
are more predictive of the phenotype than the genes outside that set, and the NEk q value corresponds to the degree to which genes within that set 
are predictive of the phenotype. Only those pathways with an NTk q value below 10-4 and a NEk q value below 1 are shown above. The relatively high 
NEk q value with respect to NTk q value values shows that these gene sets are not as significantly predictive of outcome, because they demonstrate 
significant differential expression with respect to the other gene sets. This illustrates the limitations of the sample size and nature of the current data 
set. Each pathway is annotated by ontology source (Gene Ontology [GO] or Kyoto Encyclopedia of Genes and Genomes [KEGG]). TCA, 
tricarboxylic acid.http://genomebiology.com/2007/8/10/R210 Genome Biology 2007,     Volume 8, Issue 10, Article R210       Cohen et al. R210.5
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Medical Center) between 1 April 2004 and 31 August 2004.
The included infants were at 23 to 28 weeks gestational age,
for whom parental consent to participate in the ELGAN study
had been granted and from whom supplemental umbilical
cord specimens were available. Each hospital's institutional
review board approved the study. Mothers of potential partic-
ipants signed a consent form when they were admitted to the
high-risk obstetric service and before the time of delivery.
Enrollment of infants took place at the time of birth.
Specimens were collected as part of the ELGAN study. A
study nurse collected umbilical cord tissue samples at the
time of delivery. Within 1 hour of collection, samples were
flash frozen to -70°C.
Unsupervised clustering based on Euclidean distance in expression between samples Figure 1
Unsupervised clustering based on Euclidean distance in expression between samples. Each row corresponds to a gene and each column (labeled at the 
bottom) corresponds to an infant who subsequently developed bronchopulmonary dysplasia (BPD) or a control infant.
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Total RNA was isolated from umbilical cord tissue homoge-
nates. Tissue samples were homogenized in 1 ml TRIZOL rea-
gent using a power homogenizer. Chloroform (0.2 ml) was
then added. Samples were centrifuged at no more than
12,000 g for 15 min at 2 to 8°C. RNA was precipitated from
the aqueous phase by mixing with 0.5 ml isopropyl alcohol
and centrifuged at no more than 12,000 g for 10 min at 2 to
8°C. RNA pellet was washed with 1 ml of 75% ethanol. RNA
was dissolved in 100 µl RNase-free water. The solution was
re-suspended in 100 µl water and incubated at 37°C for 5 min.
Qiagen RNeasy Mini Kit (Qiagen Inc. Valencia, CA, USA)
along with 350 µl Buffer RLT (with B-mercaptethanol) was
added to 100 µl dissolved RNA. Then, 250 µl ethanol (96% to
100%) was added to the diluted RNA. The sample (700 µl)
was applied to an RNeasy mini column placed in a 2 ml col-
lection tube, and then centrifuged at ≥ 8,000 g (≥ 10,000
rpm). buffer RPE (500 µl) was pipetted onto the RNeasy col-
umn and then centrifuged at ≥ 8,000 g  (≥ 10,000 rpm).
Northern blot analysis was performed on each sample to
confirm quality. AffymetrixÆ U133 chips (Affymetric Inc.,
Santa Clara, CA, USA) were used for hybridization.
Demographic and clinical information was gathered from
patient charts, ELGAN clinical data collection sheets, and
maternal interviews. The primary outcome of BPD was
defined as a persistent oxygen requirement at 36 weeks post-
menstrual age.
Computational analysis
Samples were evaluated by outcome of BPD and by gesta-
tional age. Single gene analysis was performed using the
multtest and qvalue packages from Bioconductor [25] to
identify those genes that were differentially expressed by the
t test and ranked by FDR.
Gene set enrichment analysis was conducted using the Sig-
pathway package of Tian and coworkers [16] using 1,000 per-
mutations for each analysis. Only the top ranked pathways
with an NTk q value below 10-4 and an NEk q value below 1.0
were included in the results. The NTk q value corresponds to
the degree to which genes within a set/pathway are more pre-
dictive of the phenotype than the genes outside that set, and
Principal component analysis of the samples at birth Figure 2
Principal component analysis of the samples at birth. The closed circles correspond to infants who did not develop bronchopulmonary dysplasia (BPD) and 
the open circles to those who did develop BPD. The centroid of the ellipsoid hull for each subgroup is illustrated with a symbol over-struck with an X 
(circle for controls and square for BPD). This plot illustrates the limited separation of these samples from the transcriptome-wide perspective. P > 0.05 for 
t-test in each of the principal components.
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the NEk q value corresponds to the degree that genes within
that set are predictive of the phenotype.
Principal component analysis was performed using the R
princomp function. Of the measured variance in the tran-
scriptome, 98.5% was captured in the first two principal com-
ponents; therefore, the plot in Figure 2 only includes the first
two components. To demonstrate the extent of the overlap, an
ellipsoid hull for each class (BPD and control infants) was cal-
culated as the ellipsoid of minimal area, such that all given
points lie just inside or on the boundary of the ellipsoid [26].
Table 5
Differentially expressed pathways in infants with BPD versus infants without BPD
Gene set/pathway NTk q value NEk q value
Regulation of cell growth (GO:0001558) 0.0 0.0
Nuclear pore complex (GO:0046930) 0.0 0.03
Negative regulation of cellular metabolism (GO:0031324) 0.0 0.04
Chromatin remodeling (GO:0016568) 0.0 0.055
PI3K-AKT signaling pathway (humanpaths) 0.0 0.1
Histone acetyltransferase binding (GO:0035035) 0.0 0.2
cAMP/Ca2+ signaling (humanpaths) 0.0 0.3
Spliceosome complex (GO:0005681) 0.0 0.9
Shown here are the pathways (with redundant pathways removed as well as those that overlapped with Table 4) that were ranked at the top of the 
list of those differentially expressed by two measures of false discovery: the NTk q value and the NEk q value. The NTk q value corresponds to the 
degree to which genes within a set/pathway are more predictive of the phenotype than the genes outside that set, and the NEk q value corresponds 
to the degree to which genes within that set are predictive of the phenotype. Only those pathways with an NTk q value below 10-4 and a NEk q value 
below 1 are shown above. Each pathway is annotated by ontology source (Gene Ontology [GO] or humanpaths). BPD, bronchopulmonary dysplasia; 
PI3K, phosphoinositide-3 kinase.
Relative expression of DNA packaging gene set relative to the overall transcriptome Figure 3
Relative expression of DNA packaging gene set relative to the overall transcriptome. The ratio of expression level of each gene in samples of infants that 
went on to develop bronchopulmonary dysplasia (BPD) against those who did not is plotted against the expression value in the infants without BPD. 
Overall, the entire transcriptome (small closed circles) is distributed around the horizontal 1.0 line (equal in BPD and control infants). However, the 229 
members of the DNA packaging gene set (large squares) are significantly biased below the 1.0 line (NTk q value = 0). This figure illustrates that, individually, 
none of the DNA packaging gene set fell significantly outside the range of variation of the entire transcriptome.
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An outline was then drawn of each corresponding ellipsoid in
Figure 2. The two P values on a t test on the samples in each
of the first two principal components were greater than 0.05,
confirming the visual impression.
Hierarchical clustering (using the R hclust function) based on
Euclidean distance of expression between samples was per-
formed using all those genes of the 54,675 that had at least
one value greater than the mean in the 54 samples.
Abbreviations
BPD, bronchopulmonary dysplasia; ELGAN, Extremely Low
Gestational Age Newborn; FDR, false discovery rate.
Box-plots of differential expression of the ten most differentially expressed genes in SWI/SNF chromatin remodeling pathway Figure 4
Box-plots of differential expression of the ten most differentially expressed genes in SWI/SNF chromatin remodeling pathway. Individually, none of these 
genes reached significance for differential expression, although the pathway was highly significantly enriched.
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